Pacira BioSciences, Inc. PCRX Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s debt issuance cost amortization?
- Pacira BioSciences, Inc. (PCRX) reported debt issuance cost amortization of $577K in Q1 2026.
- How has Pacira BioSciences, Inc.'s debt issuance cost amortization changed year-over-year?
- Pacira BioSciences, Inc.'s debt issuance cost amortization decreased by 33.4% year-over-year, from $867K to $577K.
- What is the long-term trend for Pacira BioSciences, Inc.'s debt issuance cost amortization?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s debt issuance cost amortization has grown at a 2.3% compound annual growth rate (CAGR), from $2.75M to $3.02M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).